Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 4

2(40.0%)

5Total

Phase 2(3)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03612726Recruiting

The Overall Survival of Patients With Unresectable HCC in Real-life

Role: lead

NCT03899428Phase 2Recruiting

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Role: lead

NCT03792919Phase 4Recruiting

Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)

Role: lead

NCT05470894Completed

Liver Injury After COVID-19 Vaccination

Role: lead

NCT03830749Phase 2Completed

Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura

Role: lead

NCT04428437Terminated

Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors

Role: lead

NCT04775069Phase 4Completed

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

Role: lead

NCT04775056Withdrawn

A Study to Evaluate Vaccines Against COVID-19 in the Real World

Role: lead

NCT03794258Phase 2Withdrawn

Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection

Role: lead

All 9 trials loaded